Third International Symposium on Cyclic Vomiting syndrome and Cannabinoid Hyperemesis Syndrome

点击翻译按钮获取中文摘要

Project summary Cyclic vomiting syndrome (CVS) is a common chronic disorder of gut-brain interaction (DGBI) and has a significant negative impact on patients, caregivers, and the health care system. Cannabinoid hyperemesis syndrome (CHS) has a similar clinical presentation to CVS but is thought to be due to heavy cannabis use and is being recognized with increasing frequency. How cannabis affects GI health is unclear and this is particularly important to understand given the rapid legalization of cannabis that has outpaced both funding and research. Despite CVS and CHS being important public health problems, there are significant knowledge gaps in part due to a lack of meetings that focus on this area which can foster collaboration between disciplines and accelerate research. Our current R13 grant application is a request to support a comprehensive scientific symposium, the Third International Symposium on Cyclic Vomiting Syndrome and Cannabinoid Hyperemesis Syndrome to be held at The Ohio State University in Columbus, Ohio on Nov 4-5, 2022. This will contribute to the overall goal of the NIDDK to foster collaborative research and mentorship opportunities, disseminate science-based information on digestive diseases and promote diversity and inclusion. The main objectives of our conference are 1. Provide an interdisciplinary exchange forum to advance research on biological mechanisms and clinical treatment of these interrelated disorders, CVS and CHS. 2. Foster interaction between early-stage investigators/trainees and senior investigators in basic and clinical and translational sciences to better understand mechanisms of nausea and vomiting 3. Provide a forum for health care providers and researchers to learn about various treatment approaches and novel strategies to manage CVS and CHS. 4. Promote inclusion with a particular emphasis on advancing the participation of women and individuals from underrepresented minority (URM) groups which will foster their professional development 5. Identify knowledge gaps, discuss methodological outcomes criteria for trials, and priorities for future research. Speakers will present cutting edge research on nausea and vomiting related to cyclic vomiting, cannabis use and cannabinoid hyperemesis, and migraine and discuss new modalities of therapy including neuromodulation, and CGRP antagonists in the treatment of these disorders. A scientific poster session will be held where junior investigators and trainees can present their work. The proceedings of the conference will be published in a peer-reviewed journal: Neurogastroenterology and Motility. Conference attendees will include scientists (neuroscience, gastroenterology, neurology), physicians (gastroenterology, neurologists, and geneticists), and other healthcare providers (nurses, advanced practitioners). Inclusion of URM, and early-stage investigator faculty will be a priority to facilitate the growth of the next generation of researchers.